de Andrés-Nogales F, Gay-Pobes PR, Inês M, Polanco Sánchez C, Alves D, Oyagüez I
Cost-effectiveness analysis of apixaban versus edoxaban for stroke prevention in non-valvular atrial fibrilation Portuguese patients
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019
Menchén L, de Andrés-Nogales F, García S, Sánchez-Guerrero A, Menchen B, Cábez A, Gómez S, López A, Casado MÁ, Peral C, Taxonera C
Cost-effectivenes of Tofacitinib for the Treatment of Moderate-to-severe Ulcerative Colitis After Biologic Failure or Intolerance in Spain
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019
de Andrés-Nogales F, Casado MÁ, Zarranz-Ventura J, Udaondo P, Trillo JL, Ruiz-Moreno JM, Rodriguez-Maqueda M, Poveda JL, Peralta G, Ortiz P, Martínez-Sesmero JM, Martínez-Olmos J, Ignacio E, García-Layana A, Álvarez E, Zulueta J, Mur C, Martínez M
Extended Multicriteria Decision Analysis in Diabetic Macular Edema. MULTIDEX-EMD Extension Study
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019
de Andrés-Nogales F, Ruiz-Moreno JM, Oyagüez I, Casado MA
Extended loading dose of anti-VEGF treatment in diabetic macular edema patients: A cost-consequence analysis
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019
Presa M, Varela C, Oyagüez I
Costs of cytokine release syndrome (CRS) and neurological events (NE) in patients with relapsed/refractory non-hodgkin lymphoma receiving lisocabtagene maraleucel (liso-cel) in the TRANSCEND NHL 001 clinical trial: a micro-costing study from the Spanish National Health System (NHS) perspective
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019
Presa M, Soria A, Oyagüez I, Espinosa E, Echave M, Berrocal A, Manzano JL, Suarez J, Polanco C
Nivolumab-adjuvant therapy for resected stage III-IV melanoma: a cost-effectiveness analysis for Spain
22nd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Copenhague (Dinamarca). 2-6 nov 2019
Buti M, Ledesma F, Domínguez-Hernández R, Casado MÁ, Esteban R
Is the universal population hepatitis C virus screening a cost-effective strategy? A systematic review of the economic evidence
21st Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Barcelona. 10-14 nov 2018
Rico S, Echave M, Casado MA, Soto J
Systematic review of economic evaluations based on decisión-analytic modeling of cancer drugs
21st Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Barcelona. 10-14 nov 2018
Peral C, Navarro F, Montoro M, Balsa A, Gomez S, Pablos J, Martinez-Sesmero JM, Valderrama M, Oyagüez I, de Andrés-Nogales F, Casado MÁ